Equibles does not estimate personal net worth.
Get an email with a short summary when Acumen Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ABOS alertsThe proxy statement of Acumen Pharmaceuticals, Inc. reports total compensation of $1,012,859 for Jim Doherty in fiscal 2025, including a base salary of $520,000. Disclosed compensation is on record for 2 fiscal years. Jim Doherty has spoken on 3 earnings calls and 3 other investor events across 1 company, most recently for Acumen Pharmaceuticals, Inc. on September 16, 2026. Acumen Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acumen Pharmaceuticals, Inc. includes Daniel O'Connell (CEO), Dr. George Golumbeski (Chairman and Board Member), Matthew Zuga (CFO) and 2 others.
“As we approach the readout of the Altitude AD trial, I'm pleased to take this opportunity to talk about some of the key reasons why we believe Soberna-Tug represents a differentiated opportunity for anti-A-beta disease-modifying therapies for the treatment of Alzheimer's disease.”
“As we approach the readout of the Altitude AD trial, I'm pleased to take this opportunity to talk about some of the key reasons why we believe Soberna-Tug represents a differentiated opportunity for anti-A-beta disease-modifying therapies for the treatment of Alzheimer's disease.”
“And as Dan said, beta amyloid is now a validated target for the treatment of Alzheimer's disease. And that's a huge step forward in any endeavor to find new therapies.”
“And I guess, Pete, the only other thing I would add, you asked about clinical programming. I mean, it's early days, so we're still thinking about what the early phase clinical program is going to look like.”
“And to everyone on the call, happy to be here with you today. As Dan said, we're very pleased with the candidate profiles generated in our preclinical EBD program and impressed with the level of expertise contributed by our partner, JCR Pharmaceuticals.”
Proxy statement
Start not stated–present
Last confirmed April 23, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Acumen Pharmaceuticals, Inc. (ABOS) | President and Chief Development Officer | $520,000 | $1,012,859 |
| 2024 | Acumen Pharmaceuticals, Inc. (ABOS) | President and Chief Development Officer | $458,333 | $2,182,081 |
